“I am very pleased that Orkila Capital has recognized our growth potential and chosen to invest in us,” said David Henn, CEO and founder of Cannamedical. “Our most important goal is to ensure the timely supply of medicinal cannabis to patients at all times. And we are very proud of our reputation in Germany for providing the highest levels of customer service and operating with transparency and integrity. Today we help doctors, healthcare professionals and pharmacists in Germany and other European countries to improve the quality of their patients’ lives. Our products are focused on helping people with cancer, multiple sclerosis (MS) and chronic or acute pain to live their best life with medical cannabis”
“We look for leading platforms in massive and evolving consumer markets and have found such an opportunity in Cannamedical,” said Jesse Du Bey, founder and Managing Partner of Orkila Capital. “We believe in Cannamedical’s ability to provide customers with an innovate product and help develop the potential of a huge market. Having observed the development of the North American medical cannabis market, we know medical cannabis is an important, organic medicine with few side effects, primarily targeting patients with acute and chronic conditions. Having witnessed the terrible consequences of the opiate prescription wave in the US, we believe Cannamedical can be a key player in helping German healthcare professionals provide millions of consumers with a natural therapy for chronic pain and many other acute conditions.”
Founded in 2016, Cannamedical began operating following the legalisation of medical cannabis in Germany in March 2017. The company now employs around 40 employees in Cologne, and generates a €1 million turnover.